KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) EBIAT (2016 - 2026)

Gsk has reported EBIAT over the past 18 years, most recently at $2.5 billion for Q1 2026.

  • For Q1 2026, EBIAT rose 11.09% year-over-year to $2.5 billion; the TTM value through Mar 2026 reached $9.3 billion, up 27.74%, while the annual FY2025 figure was $8.4 billion, 120.86% up from the prior year.
  • EBIAT for Q1 2026 was $2.5 billion at Gsk, up from $967.0 million in the prior quarter.
  • Over five years, EBIAT peaked at $4.2 billion in Q4 2023 and troughed at $83.2 million in Q3 2024.
  • A 5-year average of $2.1 billion and a median of $2.3 billion in 2023 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: crashed 96.33% in 2024 and later soared 3885.36% in 2025.
  • Year by year, EBIAT stood at $3.0 billion in 2022, then skyrocketed by 41.93% to $4.2 billion in 2023, then dropped by 26.94% to $3.1 billion in 2024, then tumbled by 68.41% to $967.0 million in 2025, then surged by 156.38% to $2.5 billion in 2026.
  • Business Quant data shows EBIAT for GSK at $2.5 billion in Q1 2026, $967.0 million in Q4 2025, and $3.3 billion in Q3 2025.